Is HCRTR2 a genetic risk factor for Alzheimer's disease?

Dementia and Geriatric Cognitive Disorders

Volumn 38, Issue 3-4, 2014, Pages 245-253

  Gallone, Salvatore ^a   Boschi, Silvia ^a   Rubino, Elisa ^a   De Martino, Paola ^a   Scarpini, Elio ^c   Galimberti, Daniela ^c   Fenoglio, Chiara ^c   Acutis, Pier Luigi ^b   Maniaci, Maria Grazia ^b   Pinessi, Lorenzo ^a   Rainero, Innocenzo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Liguria e Valle d'Aosta   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Alzheimer's disease; Hypocretin orexin system; Molecular model; Polymorphisms; Sleep disorders

Indexed keywords

OREXIN; OREXIN 1 RECEPTOR; OREXIN 2; OREXIN 2 RECEPTOR; UNCLASSIFIED DRUG; HCRTR1 PROTEIN, HUMAN; HCRTR2 PROTEIN, HUMAN; NEUROPEPTIDE; OREXIN RECEPTOR; OREXINS; SIGNAL PEPTIDE; OREXIN B;

AGED; ALZHEIMER DISEASE; ARTICLE; BINDING SITE; CLUSTER HEADACHE; CONTROL STRATEGY; CONTROLLED STUDY; DNA ISOLATION; FEMALE; GENE CONTROL; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; INVESTIGATIVE PROCEDURES; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MOLECULAR MODEL; POPULATION GENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP QUALITY; ALLELE; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; VERY ELDERLY; CLINICAL FEATURE; GENETIC ASSOCIATION;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NEUROPEPTIDES; OREXIN RECEPTORS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84902914582     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000359964     Document Type: Article

References (30)

1. Cruts M, Van Broeckhoven C: Molecular genetics of Alzheimer's disease. Ann Med 1998; 30: 560-565.
2. Schmidt C, Wolff M, von Ahsen N, Zerr I: Alzheimer's disease: genetic polymorphisms and rate of decline. Dement Geriatr Cogn Disord 2012; 33: 84-89.
3. Tsai S-J, Liu H-C, Liu T-Y, Cheng C-Y, Hong C-J: Association analysis for the genetic variants of the NMDA receptor subunit 2b and Alzheimer's disease. Dement Geriatr Cogn Disord 2002; 13: 91-94.
4. Infante J, Llorca J, Mateo I, Rodríguez-Rodríguez E, Sánchez-Quintana C, Sánchez-Juan P, Fernández-Viadero C, Peña N, Berciano J, Combarros O: Interaction between poly(ADP-ribose) polymerase 1 and interleukin 1A genes is associated with Alzheimer's disease risk. Dement Geriatr Cogn Disord 2007; 23: 215-218.
5. Scacchi R, Gambina G, Moretto G, Corbo RM: P21 gene variation and late-onset Alzheimer's disease in the Italian population. Dement Geriatr Cogn Disord 2013; 35: 51-57.
6. Kleiman T, Zdanys K, Black B, Rightmer T, Grey M, Garman K, Macavoy M, Gelernter J, van Dyck C: Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis. Dement Geriatr Cogn Disord 2006; 22: 73-82.
7. Stone DJ, Molony C, Suver C, Schadt EE, Potter WZ: ApoE genotyping as a progression-rate biomarker in phase II disease-modification trials for Alzheimer's disease. Pharmacogenomics J 2010; 10: 161-164
8. Thannickal TC, Lai Y-Y, Siegel JM: Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007; 130: 1586-1595.
9. Fronczek R, Overeem S, Lee SYY, Hegeman IM, van Pelt J, van Duinen SG, Lammers GJ, Swaab DF: Hypocretin (orexin) loss in Parkinson's disease. Brain 2007; 130: 1577-1585.
10. Aziz A, Fronczek R, Maat-Schieman M, Unmehopa U, Roelandse F, Overeem S, van Duinen S, Lammers G-J, Swaab D, Roos R: Hypocretin and melanin-concentrating hormone in patients with Huntington disease. Brain Pathol 2008; 18: 474-483.
11. Friedman LF, Zeitzer JM, Lin L, Hoff D, Mignot E, Peskind ER, Yesavage JA: In Alzheimer disease, increased wake fragmentation found in those with lower hypocretin-1. Neurology 2007; 68: 793-794.
12. Fronczek R, Baumann CR, Lammers GJ, Bassetti CL, Overeem S: Hypocretin/orexin disturbances in neurological disorders. Sleep Med Rev 2009; 13: 9-22.
13. Rainero I, De Martino P, Pinessi L: Hypocretins and primary headaches: neurobiology and clinical implications. Expert Rev Neurother 2008; 8: 409-416.
14. Kukkonen JP, Holmqvist T, Ammoun S, Akerman KEO: Functions of the orexinergic/hypocretinergic system. Am J Physiol Cell Physiol 2002; 283:C1567-C1591.
15. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richarson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M: Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; 92: 1 page following 696.
16. Cluderay JE, Harrison DC, Hervieu GJ: Protein distribution of the orexin-2 receptor in the rat central nervous system. Regul Pept 2002; 104: 131-144.
17. Hervieu GJ, Cluderay JE, Harrison DC, Roberts JC, Leslie RA: Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord. Neuroscience 2001; 103: 777-797.
18. Pinessi L, Binello E, De Martino P, Gallone S, Gentile S, Rainero I, Rivoiro C, Rubino E, Savi L, Valfrè W, Vaula G: The 1246G->A polymorphism of the HCRTR2 gene is not associated with migraine. Cephalalgia 2007; 27: 945-949.
19. Rainero I, Gallone S, Valfrè W, Ferrero M, Angilella G, Rivoiro C, Rubino E, De Martino P, Savi L, Ferrone M, Pinessi L: A polymorphism of the hypocretin receptor 2 gene is associated with cluster headache. Neurology 2004; 63: 1286-1288.
20. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
21. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P: Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-746.
22. Wenham PR, Price WH, Blandell G: Apolipoprotein E genotyping by one-stage PCR. Lancet 1991; 337: 1158-1159.
23. Persson B, Argos P: Prediction of transmembrane segments in proteins utilising multiple sequence alignments. J Mol Biol 1994; 237: 182-192.
24. Brady GP Jr, Stouten PF: Fast prediction and visualization of protein binding pockets with PASS. J Comput Aided Mol Des 2000; 14: 383-401.
25. Sun H, Kennedy WP, Wilbraham D, Lewis N, Calder N, Li X, Ma J, Yee KL, Ermlich S, Mangin E, Lines C, Rosen L, Chodakewitz J, Murphy GM: Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep 2013; 36: 259-267.
26. Mieda M, Sakurai T: Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status. CNS Drugs 2013; 27: 83-90.
27. Mang GM, Dürst T, Bürki H, Imobersteg S, Abramowski D, Schuepbach E, Hoyer D, Fendt M, Gee CE: The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors. Sleep 2012; 35: 1625-1635.
28. Inutsuka A, Yamanaka A: The physiological role of orexin/hypocretin neurons in the regulation of sleep/wakefulness and neuroendocrine functions. Front Endocrinol (Lausanne) 2013; 4: 18.
29. Chen L, Thakkar MM, Winston S, Bolortuya Y, Basheer R, McCarley RW: REM sleep changes in rats induced by siRNA-mediated orexin knockdown. Eur J Neurosci 2006; 24: 2039-2048.
30. Gerashchenko D, Murillo-Rodriguez E, Lin L, Xu M, Hallett L, Nishino S, Mignot E, Shiromani PJ: Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp Neurol 2003; 184: 1010-1016.